Jacobs Levy Equity Management
BCRX icon

Jacobs Levy Equity Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.56M Sell
1,004,373
-27,115
-3% -$211K 0.04% 311
2025
Q4 		$8.05M Buy
1,031,488
+661,025
+178% +$4.78M 0.03% 334
2025
Q3 		$2.81M Sell
370,463
-11,017
-3% -$91.7K 0.01% 525
2025
Q2 		$3.42M Buy
381,480
+104,621
+38% +$974K 0.01% 530
2025
Q1 		$2.08M Buy
276,859
+29,064
+12% +$234K 0.01% 652
2024
Q4 		$1.86M Sell
247,795
-119,719
-33% -$909K 0.01% 601
2024
Q3 		$2.79M Sell
367,514
-372,085
-50% -$2.83M 0.01% 538
2024
Q2 		$4.57M Buy
739,599
+583,480
+374% +$3.22M 0.02% 470
2024
Q1 		$793K Buy
156,119
+59,722
+62% +$336K ﹤0.01% 757
2023
Q4 		$577K Sell
96,397
-373,740
-79% -$2.17M ﹤0.01% 808
2023
Q3 		$3.33M Sell
470,137
-685,586
-59% -$4.93M 0.02% 460
2023
Q2 		$8.14M Sell
1,155,723
-878,620
-43% -$7.05M 0.05% 309
2023
Q1 		$17M Buy
2,034,343
+566,237
+39% +$5.45M 0.1% 215
2022
Q4 		$16.9M Buy
1,468,106
+1,051,580
+252% +$13.1M 0.11% 210
2022
Q3 		$5.25M Buy
+416,526
New +$5.36M 0.04% 385
2020
Q3 		– Sell
-75,363
Closed -$359K – 1026
2020
Q2 		$359K Buy
75,363
+57,263
+316% +$229K ﹤0.01% 850
2020
Q1 		$36K Sell
18,100
-2,098,317
-99% -$5.78M ﹤0.01% 986
2019
Q4 		$7.3M Buy
2,116,417
+488,632
+30% +$1.23M 0.07% 306
2019
Q3 		$4.66M Buy
+1,627,785
New +$5.06M 0.06% 348
2013
Q3 		– Sell
-70,400
Closed -$109K – 928
2013
Q2 		$109K Buy
+70,400
New +$121K ﹤0.01% 933

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jacobs Levy Equity Management's BCRX Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 2.6% in Q1 2026, selling an estimated $211K and leaving 1,004,373 shares worth $9.56M. The position accounts for 0.04% of the portfolio, ranked #311.

Jacobs Levy Equity Management first reported a position in BCRX in Q2 2013 and has held it in 20 quarters since. The position peaked at $17M in Q1 2023. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jacobs Levy Equity Management held 1,004,373 shares of BioCryst Pharmaceuticals worth $9.56M as of Q1 2026.
  • Jacobs Levy Equity Management sold 27,115 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $211K.
  • BioCryst Pharmaceuticals made up 0.04% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #311 holding.
  • Jacobs Levy Equity Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 20 quarters since.
  • Jacobs Levy Equity Management's BioCryst Pharmaceuticals position peaked at $17M in Q1 2023.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.